SG11202100139VA - Treatment of neuropathy with dna constructs expressing igf-1 isoforms - Google Patents

Treatment of neuropathy with dna constructs expressing igf-1 isoforms

Info

Publication number
SG11202100139VA
SG11202100139VA SG11202100139VA SG11202100139VA SG11202100139VA SG 11202100139V A SG11202100139V A SG 11202100139VA SG 11202100139V A SG11202100139V A SG 11202100139VA SG 11202100139V A SG11202100139V A SG 11202100139VA SG 11202100139V A SG11202100139V A SG 11202100139VA
Authority
SG
Singapore
Prior art keywords
isoforms
neuropathy
treatment
dna constructs
constructs expressing
Prior art date
Application number
SG11202100139VA
Other languages
English (en)
Inventor
Junghun Lee
Nayeon Lee
Kyeong Ryang Ko
Original Assignee
Neuromyon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuromyon Inc filed Critical Neuromyon Inc
Publication of SG11202100139VA publication Critical patent/SG11202100139VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11202100139VA 2018-07-17 2019-07-16 Treatment of neuropathy with dna constructs expressing igf-1 isoforms SG11202100139VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862699662P 2018-07-17 2018-07-17
PCT/IB2019/000843 WO2020016655A2 (en) 2018-07-17 2019-07-16 Treatment of neuropathy with dna constructs expressing igf-1 isoforms

Publications (1)

Publication Number Publication Date
SG11202100139VA true SG11202100139VA (en) 2021-02-25

Family

ID=69162752

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100139VA SG11202100139VA (en) 2018-07-17 2019-07-16 Treatment of neuropathy with dna constructs expressing igf-1 isoforms

Country Status (9)

Country Link
US (1) US11510999B2 (zh)
EP (1) EP3823981A4 (zh)
JP (1) JP7413629B2 (zh)
KR (1) KR20210052443A (zh)
CN (1) CN113302202B (zh)
AU (1) AU2019304569B2 (zh)
CA (1) CA3106078A1 (zh)
SG (1) SG11202100139VA (zh)
WO (1) WO2020016655A2 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3106297A1 (en) * 2018-07-19 2020-01-23 Helixmith Co., Ltd. Lyophilized pharmaceutical compositions for naked dna gene therapy
WO2023158214A1 (ko) * 2022-02-15 2023-08-24 주식회사 헬릭스미스 인슐린-유사 성장인자-1의 이형체를 이용한 근감소증 예방 또는 치료용 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024922A1 (en) * 1996-12-02 1998-06-11 Valentis, Inc. Insulin-like growth factor i (igf-i) expression system and methods of use
WO1999036103A1 (en) 1998-01-16 1999-07-22 Mcgill University Prevention and treatment of neuropathy by hepatocyte growth factor
KR20000046969A (ko) * 1998-12-31 2000-07-25 이선경 이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더
GB9926968D0 (en) * 1999-11-15 2000-01-12 Univ London Treatment of neurological disorders
KR100562824B1 (ko) * 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
JP2005530495A (ja) * 2002-04-25 2005-10-13 コーネル リサーチ ファウンデーション、インコーポレイティッド オールターナティブスプライシングされる核酸分子
JP2005534650A (ja) * 2002-06-11 2005-11-17 ザ バーナム インスティテュート エリスロポイエチンおよびインスリン様増殖因子の神経保護的相乗作用
US8613922B2 (en) * 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
CN1961071A (zh) * 2004-03-15 2007-05-09 比奥根艾迪克Ma公司 使用可选剪接在真核细胞中表达多肽多聚体的方法和构建物
GB0426154D0 (en) * 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
CN101208108A (zh) * 2005-05-02 2008-06-25 建新公司 脊髓失调症的基因治疗
CN1920021B (zh) * 2005-08-24 2010-05-05 中国医学科学院基础医学研究所 胰岛素样生长因子结合蛋白-6介导的有活性胰岛素样生长因子-ⅱ的制备方法
WO2007142651A1 (en) 2006-06-09 2007-12-13 Caritas St. Elizabeth Medical Center Of Boston, Inc. Methods and compositions for the treatment of neuropathy
AR066354A1 (es) 2007-05-01 2009-08-12 Genzyme Corp La terapia sistematica con factor-1 de crecimiento de tipo insulina reduce la neuropatia periferica diabetica y mejora la funcion renal en la nefropatia diabetica
RU2372941C2 (ru) 2007-07-02 2009-11-20 Духовлинов Илья Владимирович Фармацевтическая композиция для генной терапии заболеваний, требующих стимуляции регенераторных процессов, включая повреждения тканей человека различной этиологии, на основе синтетического модифицированного гена инсулиноподобного фактора роста человека первого типа (ифр-1, igf-1)
KR101666228B1 (ko) * 2007-09-28 2016-10-13 인트렉손 코포레이션 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
US20090202606A1 (en) 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
EP2498796B1 (en) * 2009-11-09 2017-12-27 AAL Scientifics, Inc. Treatment of heart disease
WO2012118796A1 (en) * 2011-02-28 2012-09-07 The Schepens Eye Research Institute, Inc. Compositions for controlling neuronal outgrowth
CA2964927C (en) * 2014-10-20 2019-07-30 Neuralstem, Inc. Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof
KR102245539B1 (ko) 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
WO2019221528A1 (en) * 2018-05-17 2019-11-21 Helixmith Co., Ltd. Treatment of neuropathic pain associated with chemotherapy-induced peripheral neuropathy

Also Published As

Publication number Publication date
US20200023077A1 (en) 2020-01-23
EP3823981A4 (en) 2022-04-06
CN113302202A (zh) 2021-08-24
JP7413629B2 (ja) 2024-01-16
KR20210052443A (ko) 2021-05-10
US11510999B2 (en) 2022-11-29
CN113302202B (zh) 2024-01-30
EP3823981A2 (en) 2021-05-26
WO2020016655A3 (en) 2020-03-12
AU2019304569A1 (en) 2021-03-04
WO2020016655A2 (en) 2020-01-23
JP2022511227A (ja) 2022-01-31
AU2019304569B2 (en) 2023-07-06
CA3106078A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
IL260039A (en) Plasmid templates for heterologous protein expression and methods of use
IL282233A (en) Nucleic acid structures and methods of use
IL279919A (en) Treatment of AMD using an AAV2 variant with aflibercept
ZA202006905B (en) Gene therapy constructs and methods of use
IL252917A0 (en) Vectors and vectors for gene therapy for use in the treatment of Wilson's disease
IL248508B (en) Preparations containing aav expressing dual antibody constructs and uses thereof
IL279272A (en) Nucleic acid constructs and methods of using them
IL282776A (en) Plasmid structures for cancer treatment and methods of use
SG11202100178YA (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
SG11202100139VA (en) Treatment of neuropathy with dna constructs expressing igf-1 isoforms
IL265942A (en) A nucleotide sequence expressing an exosome anchor protein for use as a component
IL274363B1 (en) Use of a specific anti-protein siRNA for the treatment of hemophilia
EP3697431A4 (en) TREATMENT OF NEUROPATHIA WITH A DNA CONSTRUCT EXPRESSING HGF ISOFORMS WITH REDUCED INTERFERENCE FROM GABAPENTIINOIDS
ZA202004867B (en) Treatment of wooden materials
IL282059A (en) Abexitide for the treatment of hyperinsulinemic hypoglycemia
EP3159411A4 (en) Vector comprising gene fragment for enhancement of recombinant protein expression and use thereof
EP3615561C0 (en) VARIANTS OF HUMAN BMP7 PROTEIN
GB201708076D0 (en) Treatment of conditions associated with impared glucose control
EP3305901A4 (en) Optimized nucleotide sequence and pharmaceutical composition based thereon with prolonged vegf transgene expression
GB201503811D0 (en) Chimeric Genes for the catalytic protein of oplophorus luciferase and use thereof